Who will judge gene-therapy research?
The NIH Recombinant DNA Advisory Committee (RAC) has been the main review body for gene-splicing experiments since the technology’s early days (SN: 2/23/85, p. 122). A RAC working group has prepared over the last two years guidelines called “points to consider” in evaluating gene-therapy proposals. A draft of this document was published in January and a revised version was to be published this summer.
